A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

— IMAGE  

Official title:

A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00299104
• Other study ID #: U3373g
• Secondary ID: WA17047
• Status: Completed
• Phase: Phase 3
• First received: March 2, 2006
• Last updated: August 20, 2013
• Start date: January 2006
• Est. completion date: July 2013

Study information

• Verified date: August 2013
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis (RA) who are naive to Methotrexate (MTX) therapy. Rheumatoid Factor (RF)-positive and RF-negative patients will be enrolled and will be allocated equally between 3 treatment arms.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 755
• Est. completion date: July 2013
• Est. primary completion date: September 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion criteria:

• Adult patients 18-80 years of age

• RA for = 2 months;

• Receiving outpatient treatment

• Patients naive to, and considered to be candidates for, methotrexate treatment

Exclusion criteria:

• Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA

• Inflammatory joint disease other than RA, or other systemic autoimmune disorder

• Diagnosis of juvenile rheumatoid arthritis, or RA before the age of 16

• Surgery within 12 weeks of study

• Previous treatment with any approved or investigational biologic agent for RA, an anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy

• Concurrent treatment with any biologic agent or DMARD other than methotrexate

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• folate
Intravenous repeating dose
• methotrexate
Oral or parenteral repeating dose
• methylprednisolone
Intravenous repeating dose
• placebo
Intravenous repeating dose
• rituximab
Intravenous repeating dose

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Genentech, Inc.	Hoffmann-La Roche

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Modified Total Sharp Score (mTSS) From Screening at Week 52	Rate of progression in structural joint damage (PJD) by change in Total Modified Sharp Score (TMSS) from screening to Week 52 in the modified intent-to-treat (MITT) population. TMSS is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint erosions and joint space narrowing.	Baseline and week 52	No
Secondary	Change From Baseline in Modified Sharp Erosion Score at Week 52	Rate of progression in structural joint damage (PJD) by change in modified Sharp erosion score from screening to Week 52. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. A score of 0 would indicate no change and higher scores represent a worsening of joint erosions.	Baseline and week 52	No
Secondary	Percentage of Patients Without Radiographic Progression at Week 52	Percentage of patients without radiographic progression at Week 52, defined as change in total modified Sharp score (TMSS) <= 0. TMSS is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change.	Baseline, Week 52	No
Secondary	Percentage of Patients Without Radiographic Progression in Total Erosion Score at Week 52	No radiographic progression is defined as a change in the total erosion score at Week 52 of less than or equal to zero.	Baseline, Week 52	No
Secondary	Change From Baseline in Modified Joint Space Narrowing (JSN) Score at Week 52	Rate of progression in structural joint damage (PJD) by change in modified joint space narrowing (JSN) from screening to Week 52. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.	Baseline and week 52	No
Secondary	Change From Baseline in the Modified Total Sharp Score at Week 24	The modified total sharp score is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint erosions and joint space narrowing.	Baseline, Week 24	No
Secondary	Change From Baseline in the Total Erosion Score at Week 24	Total Erosion Score is determined by evaluation of fourteen sites in each wrist and hand and six joints in each foot using an eight-point scale from 0 (normal: no erosions) to 3.5 (Very severe; erosions of 100% of the articular surfaces. The Total Erosion Score at Week 24 - Total Erosion Score at baseline is calculated.	Baseline, Week 24	No
Secondary	Change From Baseline in Modified Joint Space Narrowing (JSN) Score at Week 24	Joint Space Narrowing is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.	Baseline, Week 24	No
Secondary	Percentage of Participants Without Radiographic Progression at Week 24	Percentage of patients without radiographic progression at Week 24 defined as change in total modified Sharp score (TMSS) = 0. TMSS is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change.	Baseline, Week 24	No
Secondary	Percentage of Participants With American College of Rheumatology (ACR) ACR50 Response at Week 52	To achieve an ACR50 response requires at least a 50% improvement compared with baseline in both Total Joint Count and Swollen Joint Count, as well as a 50% improvement in three of five additional measurements from: the physician's global assessment of disease activity; patient's global assessment of disease activity; patient's assessment of pain; HAQ-DI (Health Assessment Questionnaire disability index); an acute phase reactant C-Reactive Protein (CRP). (If CRP was missing then Erythrocyte Sedimentation Rate (ESR) was used if available.)	Week 52	No
Secondary	Change From Baseline in the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 52	DAS28-ESR is calculated from the following formula: (0.56 * TJC) + (0.28 * SJC) + (0.70 * ln ESR) + (0.014 * GH) TJC = tender joint count, based on 28 joints SJC = swollen joint count, based on 28 joints ESR = erythrocyte sedimentation rate in mm/h GH = patient's global assessment of disease activity A DAS28-ESR score of 5.1 or above is considered to indicate high disease activity. Patients can also be defined as having low disease activity (DAS28-ESR = 3.2) or remission (DAS28-ESR < 2.6).	Baseline, Week 52	No
Secondary	Percentage of Participants With American College of Rheumatology (ACR) ACR70 Response at Week 52	To achieve an ACR70 response requires at least a 70% improvement compared with baseline in both Total Joint Count and Swollen Joint Count, as well as a 70% improvement in three of five additional measurements from: the physician's global assessment of disease activity; patient's global assessment of disease activity; patient's assessment of pain; HAQ-DI (Health Assessment Questionnaire disability index); an acute phase reactant C-Reactive Protein (CRP). (If CRP was missing then Erythrocyte Sedimentation Rate (ESR) was used if available.)	Baseline, Week 52	No
Secondary	Percentage of Participants With DAS28-ESR Remission at Week 52	The DAS28-4(ESR) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10.; Remission is defined as achieving a DAS28-ESR score of less than 2.6	Week 52	No
Secondary	Percentage of Participants With European League Against Rheumatism (EULAR) Good Response at Week 52	European League Against Rheumatism (EULAR) criteria reflects an improvement in disease activity and an attainment of a lower degree of disease activity. A good response is defined as an improvement in the DAS28-ESR of > 1.2 compared with baseline, and attainment of a DAS28-ESR of < 3.2.	Baseline, Week 52	No
Secondary	The Percentage of Participants With Major Clinical Response at Week 52	Major clinical response is defined as a continuous six-month period of success by the ACR70.; ACR70= 70% improvement compared with baseline in both Total Joint Count and Swollen Joint Count, as well as a 70% improvement in 3 of five additional measurements from: the physician's global assessment of disease activity; patient's global assessment of disease activity; patient's assessment of pain; HAQ-DI (Health Assessment Questionnaire disability index); an acute phase reactant C-Reactive Protein (CRP). (If CRP was missing then Erythrocyte Sedimentation Rate (ESR) was used if available.)	Week 52	No
Secondary	Percentage of Participants With DAS28-ESR Low Disease Activity at Week 52	The DAS28-4(ESR) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10.; Low disease activity is defined as achieving a DAS28-ESR score of less than or equal to 3.2	Week 52	No
Secondary	Percentage of Participants With American College of Rheumatology (ACR) ACR20 Response at Week 52	To achieve an ACR20 response requires at least a 20% improvement compared with baseline in both Total Joint Count and Swollen Joint Count, as well as a 20% improvement in three of five additional measurements from: the physician's global assessment of disease activity; patient's global assessment of disease activity; patient's assessment of pain; HAQ-DI (Health Assessment Questionnaire disability index); an acute phase reactant C-Reactive Protein (CRP). (If CRP was missing then Erythrocyte Sedimentation Rate (ESR) was used if available.)	Baseline, Week 52	No
Secondary	Percentage of Participants With American College of Rheumatology (ACR) ACR90 Response at Week 52	To achieve an ACR90 response requires at least a 90% improvement compared with baseline in both Total Joint Count and Swollen Joint Count, as well as a 90% improvement in three of five additional measurements from: the physician's global assessment of disease activity; patient's global assessment of disease activity; patient's assessment of pain; HAQ-DI (Health Assessment Questionnaire disability index); an acute phase reactant C-Reactive Protein (CRP). (If CRP was missing then Erythrocyte Sedimentation Rate (ESR) was used if available.)	Baseline, Week 52	No
Secondary	Change in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Score From Baseline at Week 52	FACIT-F is a 13-item questionnaire. Patients scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the patient's response to the questions (with the exception of 2 negatively stated), the greater the patient's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the patient's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the patient's health status.	Baseline, Week 52	No
Secondary	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52	The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip,and common daily activities. Each domain has at least two component questions. There are four possible responses for each component ranging from 0(without any difficulty) to 4 (unable to do).HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. A negative change from baseline indicates improvement.	Baseline, Week 52	No
Secondary	Change From Baseline in the SF-36 Physical Health Component Summary Score at Week 52 and Week 104	The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.; Means are adjusted for baseline value, Rheumatoid Factor status and region.	Baseline, Week 52, Week 104	No
Secondary	Change From Baseline in the SF-36 Mental Health Component Summary Score at Week 52 and Week 104	The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.; Means are adjusted for baseline value, Rheumatoid Factor status and region.	Baseline, Weeks 52, Week 104	No
Secondary	Percentage of Participants With Categorical Change in Health Assessment Questionnaire- Disability Index (HAQ-DI) From Baseline at Week 52	The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each domain has at least two component questions. There are four possible responses for each component on a scale of 0 (without difficulty) to 3 (unable to do). Higher scores=greater dysfunction.; Improved:HAQ-DI score change <=-0.22 Unchanged:HAQ-DI score change -0.22 to 0.22 Worsened:HAQ score => 0.22	Baseline, Week 52	No
Secondary	Percentage of Patients With Minimally Clinically Important Difference (MCID) in the SF-36 Physical Health Component Score at Week 52	MCID is defined as a change from baseline in SF-36 Physical Health Component Score of >5.42.; SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.	Baseline, Week 52	No
Secondary	Percentage of Patients With Minimally Clinically Important Difference (MCID) in the SF-36 Mental Health Component Score at Week 52	MCID is defined as a change from baseline in SF-36 Mental Health Component Score of >6.33.; SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.	Baseline, Week 52	No
Secondary	Change From Baseline in the Modified Total Sharp Score at Week 104	The modified total sharp score is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint erosions and joint space narrowing.	Baseline, Week 104	No
Secondary	Change From Baseline in the Total Erosion Score at Week 104	Total Erosion Score is determined by evaluation of fourteen sites in each wrist and hand and six joints in each foot using an eight-point scale from 0 (normal: no erosions) to 3.5 (Very severe; erosions of 100% of the articular surfaces. The change from the score at baseline to week 104 is calculated.	Baseline, Week 104	No
Secondary	Percentage of Participants Without Radiographic Progression at Week 104	Percentage of patients without radiographic progression at Week 104, defined as change in total modified Sharp score (TMSS) = 0. TMSS is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change.	Baseline, Week 104	No
Secondary	Percentage of Participants Without Radiographic Progression in the Total Erosion Score at Week 104	Total Erosion Score is determined by evaluation of fourteen sites in each wrist and hand and six joints in each foot using an eight-point scale from 0 (normal: no erosions) to 3.5 (Very severe; erosions of 100% of the articular surfaces. The score at baseline is compared to the score at week 104.; No progression is defined as a change from score at screening to week 104 =0.	Week 104	No
Secondary	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 104	The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each domain has at least two component questions. There are four possible responses for each component ranging from 0(without any difficulty) to 4 (unable to do). HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. A negative change from baseline indicates improvement.	Baseline, Week 104	No

External Links

•   Ex-U.S. Study Information (Ex-US this trial is sponsored/managed by Hoffmann-La Roche)